INGELHEIM, Germany - Tuesday, November 6th 2012 [ME NewsWire] - Results from real-world practice support evidence from clinical trials - Pradaxa® is well tolerated with a good safety profile in routine clinical setting - Benefit of Pradaxa® seen in all patients regardless of risk of bleeding and/or VTE (BUSINESS WIRE)-- New real-world data reinforces the positive safety and efficacy profile of Pradaxa® (dabigatran etexilate) in clinical practice for the prevention of venous thromboembolism (VTE) in patients undergoing total knee or hip replacement.* Data presented today at the 2012 American Heart Association Scientific Sessions highlight that treatment with Pradaxa® was well tolerated and resulted in low incidence of major bleeding events irrespective of patient risk factors.1 VTE has been estimated to be the third most common cardiovascular disorder after coronary heart disease and stroke.2 In Europe alone, it affects 1.5 million peop
...
Read more »
|
Lays Foundation for Direct-to-Patient Studies Using Patient Reported Outcomes + Medical Record Methods RESEARCH TRIANGLE PARK, N.C. - Tuesday, November 6th 2012 [ME NewsWire] (BUSINESS WIRE)-- A new pilot study from Quintiles’ Digital Patient Unit (DPU) confirms the reliability of patient-reported outcomes collected via patients recruited over the internet, demonstrating the viability of a new method for observational research that combines patient-reported outcomes and medical record data (PRO+MR). Findings demonstrate that patients can be recruited, screened and enrolled directly from online patient communities for observational studies that collect patient-reported-outcomes and clinical data with ~75% of physicians contributing medical record information. A Quintiles-authored article on the PRO+MR study, "Conducting Research on the Internet: Medical Record Data Integration with Patient-Reported Outcomes,” has been published by the peer-reviewed Journal o
...
Read more »
|
Business Wire / ME Newswire PARIS - Tuesday, November 6th 2012 Cartes 2012 Regulatory News: Gemalto (Euronext NL0000400653 GTO), the world leader in digital security, won a new Sesames award at the 2012 CARTES & IDentification industry conference for its PrintPixel security feature. The winning innovation is being showcased on the Gemalto booth, Hall 3, Entrance. "This Sesames award endorses our capacity in developing innovative products that lead to real-life applications and tangible benefits for service providers and end users, as part of our ongoing commitment to serving our customers with pioneering solutions that make them stay one step ahead,” commented Tan Teck-Lee, Gemalto’s Chief Innovation and Technology Officer. "The security features that are visible with the bare eye are always very efficient, easy to check by officials at border control and providing increased protection for citizens.” PrintPixel™ PrintPixel is a highl
...
Read more »
|
VIENNA - Tuesday, November 6th 2012 [ME NewsWire] EMC Momentum 2012 (BUSINESS WIRE)-- euroscript has received this year’s EMC IIG President Award for Customer Satisfaction at EMC Momentum 2012. For the past 25 years, euroscript has delivered top-quality services to its customers around the world, adapting to their needs, being flexible whenever required and mobilising its expertise to achieve optimum results. Since we know a satisfied customer is a loyal customer, euroscript has constantly searched for innovative approaches, developed add-ons to help customers get the best out of their technology and implemented architecture-based solutions suited to a wide range of highly specific environments. Today, by presenting euroscript with this prestigious award, EMC recognizes euroscript’s excellence in delivering customer satisfaction and its ability to exceed customer expectations by providing the highest levels of satisfaction in terms of service and solutions.<
...
Read more »
|
INGELHEIM, Germany - Tuesday, November 6th 2012 New data presented at the AHA’s Scientific Sessions demonstrate antibody fragment antidote to be highly selective and specific for rapid reversal of the anticoagulant effect of dabigatran After successful completion of the pre-clinical research phase, Boehringer Ingelheim initiated the clinical phase I trial development of a specific antidote as a potential additional option for patient management during rare critical care situations and/or emergency surgery Despite the absence of a specific antidote, dabigatran proven to be highly effective for stroke prevention without increasing rate of bleeding versus warfarin (BUSINESS WIRE/ ME NewsWire)-- For Non-US, Non-UK & Non-Canadian Media Only New findings presented at the 2012 American Heart Association Scientific Sessions in Los Angeles provide early indications that a highly specific and selective antido
...
Read more »
|
BUSINESS WIRE / ME NewsWire - INGELHEIM, Germany - Tuesday, November 6th 2012 New FDA data safety assessment supports previous clinical evidence on the safety of the anticoagulation therapy and reports new Pradaxa® and warfarin patients to have similar bleeding rates Comprehensive efficacy and safety evaluation by the EMA leads to recommendation for renewal of the marketing authorisation for Pradaxa® to ensure ongoing patient benefit For Non-US, Non-UK & Non-Canadian Media Only Following independent regulatory appraisals of the safety and efficacy of the anticoagulation therapy Pradaxa®, both the U.S. Food and Drug Administration (FDA) and European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) have reconfirmed the positive benefit-risk profile of the treatment for prevention of stroke in patients with atrial fibrillation (AF)*. On Friday 2nd November, the FDA published the results of a Mini-Sentin
...
Read more »
|
BOSTON - Monday, November 5th 2012 [ME NewsWire] Sapient EngagedNowSM Delivers Innovative Multi-Channel Customer Experiences through a Unified Platform (BUSINESS WIRE)-- SapientNitro, part of Sapient (NASDAQ: SAPE), today announced the launch of Sapient EngagedNowSM, a robust cloud-based platform offering that gives marketers the ability to better engage today’s on-the-go consumers across an increasing array of digitally enhanced channels. With EngagedNow, brands can create immersive, multi-channel customer experiences -- without having to design, develop and support the infrastructure needed to enable these experiences. EngagedNow is a platform suite that can be used broadly by marketers across a range of industries. The suite also includes unique offerings and modular capabilities to support the specific needs of industry verticals, including sports & entertainment (Sapient EngagedFanSM) and travel (Sapient EngagedTravelerSM). EngagedNow is the first end-to-
...
Read more »
|
|